AG946 C 003 — ASO

By Hello Thread on AppTrack Ninja.

Participant Study App

This app is intended for use by participants in the AG946 C 003 study and requires an invitation and activation code from the study site to register. A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter, Dose-Finding, Efficacy, and Safety Study of Tebapivat in Subjects with Sickle Cell Disease. This study has been reviewed and approved by the appropriate regulatory body, e.g. Institutional Review Board (IRB) or Independent Ethics Committee (IEC). Key App Features: - Patient Onboarding – complete study app registration and education - Activities – complete scheduled or on-deman…

Categories: Medical, Health & Fitness

Keyword visibility, ranked search terms and daily position movement for AG946 C 003.